# US 2006/0041136 A1 · Method for manufacturing crystalline form I of clopidogrel hydrogen sulphate

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2006/0041136 A1
- Document ID: US20060041136A1
- Status: Published application
- Kind: A1
- Application number: 10/525,341
- Filed: 2003-08-26
- Published: 2006-02-23
- Earliest claimed: 2002-08-27
- Assignees: Zentiva, A.S.
- Inventors: Miroshlav Veverka; Stefan Vodny; Eva Veverkova; Josef Hajicek; Hana Stepankova
- Web page: https://patentgrep.com/patent/US20060041136A1

## CPC

- C07D 495/04: Ortho-condensed systems
- A61P 7/02: Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A method for manufacturing hydrogen sulphate (alpha S) of the alpha-(2-chlorophenyl)-6,7dihydrothieno[3,2-c]pyridine-5(4H)-acetic acid methyl ester (clopidogrel hydrogen sulphate) of formula I, in crystalline Form I, wherein the compound of formula is separated out of a solution of clopidogrel in the form of the free base or salt in a solvent selected from the series of primary, secondary or tertiary C1-C5 alcohols, their esters with C1-C4 carboxylic acids, or optionally of mixtures thereof.

## Claims

### Claim 1

A method for manufacturing hydrogen sulphate (alpha S) of the alpha-(2-chlorophenyl)-6,7-dihydro-thieno[3,2-c]pyridine-5(4H)-acetic acid methyl ester (clopidogrel hydrogen sulphate) of formula I
in crystalline Form I, characterized in that the compound of formula I is separated out of a solution of clopidogrel in the form of the free base or salt in a solvent selected from the series of primary, secondary or tertiary C1-C5 alcohols or their esters with C1-C4 carboxylic acids, or optionally of mixtures thereof.

### Claim 2 (depends on 1)

The method according to claim 1, characterized in that the compound of formula I is crystallised out of a solution of clopidogrel hydrogen sulphate by cooling down.

### Claim 3 (depends on 1)

The method according to claim 1, characterized in that the compound of formula I is precipitated out of a solution of the base or of its salt by adding of 0.6 to 1.1 equivalent of sulphuric acid.

### Claim 4 (depends on 3)

The method according to claim 3, characterized in that the compound of formula I is precipitated out of a solution in a C1 to C5 alcohol.

### Claim 5 (depends on 4)

The method according to claim 4, characterized in that the precipitation is performed out of a solution in 2-propanol.

### Claim 6 (depends on 5)

The method according to claim 5, characterized in that the precipitation is performed at a temperature between −5 and 15° C. and the solution is inoculated with crystals of Form I.

### Claim 7 (depends on 6)

Clopidrogrel hydrogen sulphate of formula I, manufactured by the method according to the claim 6, having the contents of 98% of crystalline Form I at minimum.
